{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,20]],"date-time":"2025-11-20T13:11:58Z","timestamp":1763644318068,"version":"3.37.3"},"reference-count":37,"publisher":"Oxford University Press (OUP)","issue":"11","license":[{"start":{"date-parts":[[2024,7,19]],"date-time":"2024-07-19T00:00:00Z","timestamp":1721347200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003645","name":"National Cancer Center","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003645","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Ministry of Health & Welfare, Republic of Korea"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,11,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>The physical dependence on prescription opioids among cancer survivors remains an under-investigated area, with a scarcity of well-designed prospective studies.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>This single-arm, phase-2 clinical trial in Korea assessed the efficacy and safety of a transdermal buprenorphine patch (TBP) in managing physical dependence on prescription opioids in cancer survivors, as confirmed through the DSM-5 criteria or psychiatric consultation for opioid withdrawal. This study involved a 4-phase treatment protocol of screening, induction\/stabilization, discontinuation, and monitoring. The primary outcome was the rate of successful opioid discontinuation, as measured by a negative urine-drug screening at 8 weeks. Key secondary outcomes included the resumption of prescribed opioids, changes in both the Clinical Opioid Withdrawal Scale (COWS) and morphine equivalent daily dose (MEDD), and assessments related to the psychological and physiological aspects of dependence and safety.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Thirty-one participants were enrolled. In the intention-to-treat population, the success rate of opioid discontinuation was 58%, with only 2 participants experiencing a resumption of prescribed opioids. Significant reductions were observed in MEDD, which decreased from 98 to 26 mg\/day (P\u2005&amp;lt;\u2005.001), and COWS scores, which decreased from 5.5 to 2.8 (P\u2005&amp;lt;\u2005.001). Desire to use opioids reduced from 7.0 to 3.0 on a 10-point numeric rating scale (P\u2005&amp;lt;\u2005.001). Toxicities related to TBP were mild and manageable, without severe precipitated withdrawal symptoms.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>TBP may be considered as an alternative therapeutic option in cancer survivors physically dependent on prescription opioids, especially where sublingual formulations are unavailable.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/oncolo\/oyae176","type":"journal-article","created":{"date-parts":[[2024,7,19]],"date-time":"2024-07-19T15:03:38Z","timestamp":1721401418000},"page":"e1593-e1603","source":"Crossref","is-referenced-by-count":3,"title":["Efficacy of transdermal buprenorphine patch for managing withdrawal symptoms in patients with cancer physically dependent on prescription opioids"],"prefix":"10.1093","volume":"29","author":[{"given":"Jung Hun","family":"Kang","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, Gyeongsang National University College of Medicine , Jinju ,","place":["Korea"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kyung Hee","family":"Lee","sequence":"additional","affiliation":[{"name":"Department of Hematology-Oncology, Yeungnam University College of Medicine , Daegu ,","place":["Korea"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seok Jae","family":"Huh","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Dong-A University College of Medicine , Busan ,","place":["Korea"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seong-Hoon","family":"Shin","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Kosin University College of Medicine , Busan ,","place":["Korea"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Il Hwan","family":"Kim","sequence":"additional","affiliation":[{"name":"Division of Oncology, Department of Internal Medicine, Haeundae Paik Hospital, Inje University College of Medicine , Busan ,","place":["Korea"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"In Gyu","family":"Hwang","sequence":"additional","affiliation":[{"name":"Division of Hematology\/Oncology, Department of Internal Medicine, Chung-Ang University Hospital, Chung-Ang University College of Medicine , Seoul ,","place":["Korea"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dong-Hoe","family":"Koo","sequence":"additional","affiliation":[{"name":"Division of Hematology\/Oncology, Department of Internal Medicine, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine , Seoul ,","place":["Korea"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dongyun","family":"Lee","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Gyeongsang National University Changwon Hospital, Gyeongsang National University College of Medicine , Changwon ,","place":["Korea"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Su-Jin","family":"Koh","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology, Ulsan University Hospital, Ulsan University College of Medicine , Ulsan ,","place":["Korea"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seyoung","family":"Seo","sequence":"additional","affiliation":[{"name":"Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine , Seoul ,","place":["Korea"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guk Jin","family":"Lee","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Bucheon St. Mary\u2019s Hospital, College of Medicine, The Catholic University of Korea , Bucheon ,","place":["Korea"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sang Hoon","family":"Chun","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Bucheon St. Mary\u2019s Hospital, College of Medicine, The Catholic University of Korea , Bucheon ,","place":["Korea"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun Ho","family":"Ji","sequence":"additional","affiliation":[{"name":"Division of Hematology-Oncology, Department of Internal Medicine, Samsung Changwon Hospital, Sungkyunkwan University School of Medicine , Changwon ,","place":["Korea"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sung Yong","family":"Oh","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Dong-A University College of Medicine , Busan ,","place":["Korea"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jung Woo","family":"Choi","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Gyeongsang National University College of Medicine , Jinju ,","place":["Korea"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3025-6096","authenticated-orcid":false,"given":"Se-Il","family":"Go","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Gyeongsang National University Changwon Hospital, Gyeongsang National University College of Medicine , Changwon ,","place":["Korea"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2024,7,19]]},"reference":[{"issue":"17","key":"2024110817090973300_CIT0001","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1001\/jama.2018.2844","article-title":"Changes in synthetic opioid involvement in drug overdose deaths in the United States, 2010-2016","volume":"319","author":"Jones","year":"2018","journal-title":"JAMA"},{"issue":"7","key":"2024110817090973300_CIT0002","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1001\/jamaoncol.2020.0799","article-title":"Incidence of opioid-associated deaths in cancer survivors in the United States, 2006-2016: a population study of the opioid epidemic","volume":"6","author":"Chino","year":"2020","journal-title":"JAMA Oncol"},{"issue":"23","key":"2024110817090973300_CIT0003","doi-asserted-by":"crossref","first-page":"e185","DOI":"10.3346\/jkms.2022.37.e185","article-title":"Survey of opioid risk tool among cancer patients receiving opioid analgesics","volume":"37","author":"Oh","year":"2022","journal-title":"J Korean Med Sci"},{"issue":"4","key":"2024110817090973300_CIT0004","doi-asserted-by":"crossref","first-page":"185","DOI":"10.14475\/jhpc.2023.26.4.185","article-title":"Proportion of non-medical opioid use of prescription opioids among cancer patients in Korea","volume":"26","author":"Go","year":"2023","journal-title":"J Hosp Palliat Care"},{"issue":"1","key":"2024110817090973300_CIT0005","doi-asserted-by":"crossref","first-page":"pkab095","DOI":"10.1093\/jncics\/pkab095","article-title":"Trends in opioid use among cancer patients in the United States: 2013-2018","volume":"6","author":"Chen","year":"2022","journal-title":"JNCI Cancer Spectr"},{"issue":"26","key":"2024110817090973300_CIT0006","doi-asserted-by":"crossref","first-page":"2948","DOI":"10.1200\/JCO.21.00476","article-title":"US trends in opioid access among patients with poor prognosis cancer near the end-of-life","volume":"39","author":"Enzinger","year":"2021","journal-title":"J Clin Oncol"},{"issue":"3","key":"2024110817090973300_CIT0007","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/j.psc.2010.04.012","article-title":"Cognitive behavioral therapy for substance use disorders","volume":"33","author":"McHugh","year":"2010","journal-title":"Psychiatr Clin North Am"},{"key":"2024110817090973300_CIT0008","doi-asserted-by":"crossref","first-page":"143","DOI":"10.2147\/SAR.S81535","article-title":"Benefits of peer support groups in the treatment of addiction","volume":"7","author":"Tracy","year":"2016","journal-title":"Subst Abuse Rehabil"},{"issue":"12","key":"2024110817090973300_CIT0009","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1001\/archgenpsychiatry.2011.121","article-title":"Adjunctive counseling during brief and extended buprenorphine-naloxone treatment for prescription opioid dependence: a 2-phase randomized controlled trial","volume":"68","author":"Weiss","year":"2011","journal-title":"Arch Gen Psychiatry"},{"issue":"2","key":"2024110817090973300_CIT0010","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1176\/appi.ps.201300256","article-title":"Medication-assisted treatment with buprenorphine: assessing the evidence","volume":"65","author":"Thomas","year":"2014","journal-title":"Psychiatr Serv"},{"issue":"3","key":"2024110817090973300_CIT0011","doi-asserted-by":"crossref","first-page":"299","DOI":"10.31887\/DCNS.2017.19.3\/msoyka","article-title":"Treatment of opioid dependence with buprenorphine: current update","volume":"19","author":"Soyka","year":"2017","journal-title":"Dialogues Clin Neurosci"},{"volume-title":"Clinical Guidelines for the Use of Buprenorphine in the Treatment of Opioid Addiction. Treatment Improvement Protocol (TIP) Series 40. DHHS Publication No. (SMA) 04-3939","year":"2004","author":"Center for Substance Abuse Treatment","key":"2024110817090973300_CIT0012"},{"volume-title":"Medications for Opioid Use Disorder. Treatment Improvement Protocol (TIP) Series 63, Full Document. HHS Publication No. (SMA) 195063FULLDOC","year":"2018","author":"Substance Abuse and Mental Health Services Administration","key":"2024110817090973300_CIT0013"},{"issue":"12","key":"2024110817090973300_CIT0014","doi-asserted-by":"crossref","first-page":"e2139968","DOI":"10.1001\/jamanetworkopen.2021.39968","article-title":"Expert panel consensus on management of advanced cancer-related pain in individuals with opioid use disorder","volume":"4","author":"Merlin","year":"2021","journal-title":"JAMA Netw Open"},{"issue":"8","key":"2024110817090973300_CIT0015","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1001\/jamaoncol.2022.2191","article-title":"Consensus-based guidance on opioid management in individuals with advanced cancer-related pain and opioid misuse or use disorder","volume":"8","author":"Fitzgerald Jones","year":"2022","journal-title":"JAMA Oncol"},{"issue":"2","key":"2024110817090973300_CIT0016","doi-asserted-by":"crossref","first-page":"111","DOI":"10.5055\/jom.2020.0557","article-title":"Successful use of buprenorphine-naloxone medication-assisted program to treat concurrent pain and opioid addiction after cancer therapy","volume":"16","author":"Moryl","year":"2020","journal-title":"J Opioid Manag"},{"issue":"10","key":"2024110817090973300_CIT0017","doi-asserted-by":"crossref","first-page":"1648","DOI":"10.1111\/j.1360-0443.2007.01944.x","article-title":"Evaluation of a transdermal buprenorphine formulation in opioid detoxification","volume":"102","author":"Lanier","year":"2007","journal-title":"Addiction"},{"issue":"2","key":"2024110817090973300_CIT0018","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1007\/s00213-008-1105-z","article-title":"Opioid detoxification via single 7-day application of a buprenorphine transdermal patch: an open-label evaluation","volume":"198","author":"Lanier","year":"2008","journal-title":"Psychopharmacology (Berl)"},{"issue":"1","key":"2024110817090973300_CIT0019","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1111\/ajad.12964","article-title":"Case series: limited opioid withdrawal with use of transdermal buprenorphine to bridge to sublingual buprenorphine in hospitalized patients","volume":"29","author":"Tang","year":"2020","journal-title":"Am J Addict"},{"issue":"3","key":"2024110817090973300_CIT0020","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1001\/jamainternmed.2018.6749","article-title":"Initiating opioid agonist treatment for opioid use disorder in the inpatient setting: a teachable moment","volume":"179","author":"Raheemullah","year":"2019","journal-title":"JAMA Intern Med"},{"issue":"4","key":"2024110817090973300_CIT0021","doi-asserted-by":"crossref","first-page":"152","DOI":"10.14475\/kjhpc.2018.21.4.152","article-title":"Successful treatment with transdermal buprenorphine patch in opioid-dependent cancer patients: case series","volume":"21","author":"Go","year":"2018","journal-title":"J Hosp Palliat Care"},{"issue":"1","key":"2024110817090973300_CIT0022","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1172\/JCI134708","article-title":"Medications for opioid use disorders: clinical and pharmacological considerations","volume":"130","author":"Volkow","year":"2020","journal-title":"J Clin Invest"},{"key":"2024110817090973300_CIT0023","doi-asserted-by":"crossref","DOI":"10.1176\/appi.books.9780890425596","volume-title":"Diagnostic and statistical manual of mental disorders: DSM-5\u2122","author":"American Psychiatric Association, DSM-5 Task Force","year":"2013","edition":"5"},{"issue":"2","key":"2024110817090973300_CIT0024","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.clinthera.2005.02.012","article-title":"Equipotent doses of transdermal fentanyl and transdermal buprenorphine in patients with cancer and noncancer pain: results of a retrospective cohort study","volume":"27","author":"Sittl","year":"2005","journal-title":"Clin Ther"},{"year":"2024","author":"National Comprehensive Cancer Network","key":"2024110817090973300_CIT0025"},{"author":"Crawford","key":"2024110817090973300_CIT0026","article-title":"Background, process, and outcomes: development of a collaborative international opioid conversion and rotation ratios table"},{"issue":"2","key":"2024110817090973300_CIT0027","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1111\/ajad.12862","article-title":"Review article: Effective management of opioid withdrawal symptoms: a gateway to opioid dependence treatment","volume":"28","author":"Kosten","year":"2019","journal-title":"Am J Addict"},{"issue":"2","key":"2024110817090973300_CIT0028","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1080\/02791072.2003.10400007","article-title":"The Clinical Opiate Withdrawal Scale (COWS)","volume":"35","author":"Wesson","year":"2003","journal-title":"J Psychoactive Drugs"},{"author":"U.S Food and Drug Administration","key":"2024110817090973300_CIT0029"},{"key":"2024110817090973300_CIT0030","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.drugalcdep.2015.02.030","article-title":"Long-term outcomes from the national drug abuse treatment clinical trials network prescription opioid addiction treatment study","volume":"150","author":"Weiss","year":"2015","journal-title":"Drug Alcohol Depend"},{"issue":"4","key":"2024110817090973300_CIT0031","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1111\/add.13238","article-title":"Long-term outcomes after randomization to buprenorphine\/naloxone versus methadone in a multi-site trial","volume":"111","author":"Hser","year":"2016","journal-title":"Addiction"},{"issue":"9","key":"2024110817090973300_CIT0032","doi-asserted-by":"crossref","first-page":"e2334540","DOI":"10.1001\/jamanetworkopen.2023.34540","article-title":"Buprenorphine dose and time to discontinuation among patients with opioid use disorder in the era of fentanyl","volume":"6","author":"Chambers","year":"2023","journal-title":"JAMA Netw Open"},{"issue":"3","key":"2024110817090973300_CIT0033","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1097\/MJT.0b013e31828bfb6e","article-title":"Transdermal buprenorphine, opioid rotation to sublingual buprenorphine, and the avoidance of precipitated withdrawal: a review of the literature and demonstration in three chronic pain patients treated with butrans","volume":"22","author":"Kornfeld","year":"2015","journal-title":"Am J Ther"},{"issue":"4","key":"2024110817090973300_CIT0034","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1007\/s40262-020-00957-0","article-title":"Population pharmacokinetics of a monthly buprenorphine depot injection for the treatment of opioid use disorder: a combined analysis of phase II and phase III trials","volume":"60","author":"Jones","year":"2021","journal-title":"Clin Pharmacokinet"},{"key":"2024110817090973300_CIT0035","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.ajp.2019.02.002","article-title":"Transdermal buprenorphine patch: potential for role in management of opioid dependence","volume":"40","author":"Dhawan","year":"2019","journal-title":"Asian J Psychiatr"},{"key":"2024110817090973300_CIT0036","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.jsat.2014.12.011","article-title":"Discontinuation of buprenorphine maintenance therapy: perspectives and outcomes","volume":"52","author":"Bentzley","year":"2015","journal-title":"J Subst Abuse Treat"},{"issue":"4","key":"2024110817090973300_CIT0037","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1097\/j.pain.0000000000002783","article-title":"Delphi study to explore a new diagnosis for \u201cineffective\u201d long-term opioid therapy for chronic pain","volume":"164","author":"Edmond","year":"2023","journal-title":"Pain"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/29\/11\/e1593\/60541859\/oyae176.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/29\/11\/e1593\/60541859\/oyae176.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,8]],"date-time":"2024-11-08T17:09:41Z","timestamp":1731085781000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/29\/11\/e1593\/7717083"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,19]]},"references-count":37,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2024,7,19]]},"published-print":{"date-parts":[[2024,11,4]]}},"URL":"https:\/\/doi.org\/10.1093\/oncolo\/oyae176","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"type":"print","value":"1083-7159"},{"type":"electronic","value":"1549-490X"}],"subject":[],"published-other":{"date-parts":[[2024,11]]},"published":{"date-parts":[[2024,7,19]]}}}